Glenmark receives USFDA approval for fluocinonide cream
As per IMS Health, fluocinonide cream garnered annual sales of approximately $ 103 million in the 12 month period ending March 2014
Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Limited, on July 15, 2014, was granted final approval by the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for fluocinonide cream USP 0.1%, the generic version of Vanos Cream by Medicis.
Fluocinonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. According to IMS Health sales data for the 12 month period ending March 2014, fluocinonide cream garnered annual sales of approximately $ 103 million.
Fluocinonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. According to IMS Health sales data for the 12 month period ending March 2014, fluocinonide cream garnered annual sales of approximately $ 103 million.